Single large study or meta-analysis parameters: Choosing the most appropriate tool for Down syndrome screening in the first trimester

Prenatal Diagnosis

Volumn 26, Issue 12, 2006, Pages 1124-1130

  Ramos Corpas, Domingo ^a   Santiago, Juan C ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Down syndrome; Meta analyses; Nuchal translucency; Prenatal screening; Statistics

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DOWN SYNDROME; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; PARAMETER; POPULATION RESEARCH; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FETAL DISEASES; HUMANS; MASS SCREENING; MATERNAL AGE; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; SPAIN;

EID: 33845597588     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1568     Document Type: Article

References (31)

1. Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH. 2005. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 192: 1761-1767.
2. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
3. Brambati B, Macintosh MCM, Teisner B, et al. 1993. Low maternal serum level of pregnancy associated plasma protein (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 100: 324-326.
4. Cuckle H, Arbuzova S. 2004. Multianalyte maternal serum screening for chromosomal defects. In Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment (5th edn), Milunsky A (ed.). John Hopkins University Press: Baltimore, MD; 795-835.
5. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387-402.
6. Cuckle H, Benn P, Wright D. 2005. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 29: 252-257.
7. Forest JC, Masse J, Rousseau F, Moutquin JM, Brideau NA, Belanger M. 1995. Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. Clin Biochem 28(4): 443-449.
8. Hyett JA, Perdu M, Sharland GK, Snijders RS, Nicolaides KH. 1997. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol 10(4): 242-246.
9. Knight GJ. 1996. Quality assessment of a prenatal screening program. Early Hum Dev 30(Suppl. 47): S49-S53.
10. Macri JN, Kasturi RV, Krantz DA, et al. 1990. Maternal serum Down syndrome screening: free beta protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 163: 1248-1253.
11. Morris JK, Wald NJ, Watt HC. 1999. Fetal loss in Down syndrome pregnancies. Prenat Diagn 19: 142-145.
12. Nicolaides KH. 2004. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 191: 45-67.
13. Nicolaides KH, Heath V, Cicero S. 2002. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 22: 308-315.
14. Reynolds TM. 2004. Fixing detection rates to evaluate false positive rates. A statistical illusion? Chemical Pathology 1: 12-13.
15. Reynolds T, Ellis A, Jones R. 2004. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input. Ann Clin Biochem 41: 464-468.
16. Royston P. 1991. Constructing time-specific reference ranges. Stat Med 10: 675-690.
17. Royston P, Thompson SG. 1992. Model-based screening by risk with application to Down's syndrome. Stat Med 11: 257-268.
18. Royston P, Wright EM. 1998. How to construct 'normal ranges' for fetal variables. Ultrasound Obstet Gynecol 11: 30-38.
19. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. 1999. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 156: 460-461.
20. Spencer K. 2001. What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 21: 788-789.
21. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
22. Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH. 2003. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22: 142-148.
23. UK National Screening Committee. 2004. Antenatal screening-working standards. National Down's Syndrome Screening Programme for England. http://www.screening.nhs.uk/downs/ working_standards.pdf (Accessed 9 May 2006).
24. Wald NJ, Hackshaw AK. 1997. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 17: 821-829.
25. Wald NJ, Hackshaw AK, Huttly W, Kennard A. 1996. Empirical validation of risk screening for Down's syndrome. J Med Screen 3: 185-187.
26. Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. 2004a. SURUSS in perspective. Br J Obstet Gynaecol 111: 521-531.
27. Wald N, Rodeck C, Hackshaw A, Rudnicka A. 2004b. Correlations between nuchal translucency and serum markers in SURUSS. Prenat Diagn 24: 835-836.
28. Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. 2005. SURUSS in perspective. Semin Perinatol 29: 225-235.
29. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. 2003. SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the serum, urine and ultrasound screening study (SURUSS). Health Technol Assess 7: 1-77.
30. Wapner R, Thom E, Simpson JL, et al. 2003. First trimester maternal serum biochemistry and fetal nuchal translucency screening (BUN) study group. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
31. Wøjdemann KR, Christiansen M, Sundberg K, et al. 2001. Quality assessment in prospective nuchal translucency screening for Down syndrome. Ultrasound Obstet Gynecol 18: 641-644.